biostudies-literatureUnknown8(3)Al Hadidi S<h4>Abstract</h4>The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan-based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)-defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP-defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 3Blood advances703-707https://www.ebi.ac.uk/biostudies/studies/S-EPMC10845028biostudies-literatureThree years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.PMC10845028Sawyer JBailey CBarlogie BAbabneh OEAl Hadidi SPanozzo SThanendrarajan SShaughnessy JDCottler-Fox MSmith RZangari MTricot GAlapat DZhan FSchinke CDvan Rhee FfalseThree years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.<h4>Abstract</h4>The total therapy (TT) IIIB phase 2 study incorporated bortezomib into tandem melphalan-based hematopoietic stem cell transplantation with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide for induction/consolidation and bortezomib, lenalidomide, and dexamethasone (VRD) for maintenance in patients with newly diagnosed multiple myeloma (MM). This updated analysis presents a 15.4-year median follow-up. Of 177 patients, 21% patients had gene expression profile (GEP)-defined high-risk MM. 15-year progression free survival (PFS) was 27.9%. Median PFS was better in GEP-defined low-risk patients at 7.8 years and in International Staging System stage 1 patients at 8.7 years. Overall, median OS was 9.1 years, and 15-year overall survival (OS) was 32024-01-01T00:00:00Z2024 Feb2026-07-15T09:20:43.365Z2024-11-08T09:54:13.529ZS-EPMC108450283805203710.1182/bloodadvances.2023011601